Human immunodeficiency virus (HIV) infection selectively targets the striatum, a region rich in opioid receptor-expressing neural cells, resulting in gliosis and neuronal losses. Opioids can be neuroprotective or can promote neurodegeneration. To determine whether opioids modify the response of neurons to human immunodeficiency virus type 1 (HIV-1) Tat protein-induced neurotoxicity, neural cell cultures from mouse striatum were initially characterized for μ and/or κ opioid receptor immunoreactivity. These cultures were continuously treated with morphine, the opioid antagonist naloxone, and/or HIV-1 Tat (1-72) protein, a non-neurotoxic HIV-1 Tat deletion mutant (TatΔ31-61) protein, or immunoneutralized HIV-1 Tat (1-72) protein. Neuronal and astrocyte viability was examined by ethidium monoazide exclusion, and by apoptotic changes in nuclear heterochromatin using Hoechst 33342. Morphine (10 nM, 100 nM or 1 μM) significantly increased Tat-induced (100 or 200 nM) neuronal losses by about two-fold at 24 h following exposure. The synergistic effects of morphine and Tat were prevented by naloxone (3 μM), indicating the involvement of opioid receptors. Furthermore, morphine was not toxic when combined with mutant Tat or immunoneutralized Tat. Neuronal losses were accompanied by chromatin condensation and pyknosis. Astrocyte viability was unaffected. These findings demonstrate that acute opioid exposure can exacerbate the neurodegenerative effect of HIV-1 Tat protein in striatal neurons, and infer a means by which opioids may hasten the progression of HIV-associated dementia.
|Number of pages||9|
|State||Published - Feb 5 2001|
Bibliographical noteFunding Information:
This work was supported by NIH grants DA 06204, DA13559 and NS 39253. We thank Dr Robert P. Elde for providing anti-μ and κ opioid receptor antisera, and Carol Anderson for technical assistance.
- Acquired immunodeficiency syndrome (AIDS)
- Basal ganglia
- Drug abuse
ASJC Scopus subject areas
- Neuroscience (all)